Nrg Lu-005: A Phase II/III Randomized Study Of Chemoradiation Versus Chemoradiation Plus Atezolizumab Immunotherapy In Limited Stage Small Cell Lung Cancer (Ls-Sclc)
Posted Date: Feb 5, 2020
- Investigator: Emily Daugherty
- Specialties: Cancer, Lung Cancer, Oncology, Pulmonary Diseases, Radiation Oncology
- Type of Study: Drug
The purpose of this study is to compare progression free survival (PFS) and overall survival for patients with limited stage small cell lung cancer (LS-SCLC) treated with chemoradiation +/- atezolizumab.
Criteria:
Patients Over Age 18 Who Have A Proven Diagnosis Of Limited Stage Small Cell Lung Cancer, Ecog 0-2 Who Have No Prior Malignancy Within 2 Past Two Years And No Prior Radiation To Chest
Keywords:
Immunotherapy, Small Cell Lung Cancer, Radiation Therapy
For More Information:
Dr. Emily Daugherty, Md
513-584-7698
daugheec@ucmail.uc.edu